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Abstract NKG2D is one of the most intensively studied
immune receptors of the past decade. Its unique binding
and signaling properties, expression pattern, and functions
have been attracting much interest within the ﬁeld due to
its potent antiviral and anti-tumor properties. As an acti-
vating receptor, NKG2D is expressed on cells of the innate
and adaptive immune system. It recognizes stress-induced
MHC class I-like ligands and acts as a molecular sensor for
cells jeopardized by viral infections or DNA damage.
Although the activating functions of NKG2D have been
well documented, recent analysis of NKG2D-deﬁcient
mice suggests that this receptor may have a regulatory role
during NK cell development. In this review, we will revisit
known aspects of NKG2D functions and present new
insights in the proposed inﬂuence of this molecule on
hematopoietic differentiation.
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The NKG2D receptor and its ligands
NKG2D is a potent activating receptor expressed on vir-
tually all NK cells [1]. It is also expressed on most NKT
cells and subpopulations of cd T cells [2]. All human CD8
?
ab T cells express NKG2D, whereas NKG2D expression
on CD4
? ab T cells has primarily been reported in some
pathological conditions [3–6]. Mice express NKG2D only
on activated and memory type ab CD8
? T cells. Thus,
NKG2D is expressed on effector cells of both innate and
adaptive immune responses and is implicated in the sur-
veillance of viral infections and cancers as well as in some
autoimmune processes and transplantation reactions
[7–15].
NKG2D is a C-type lectin-like type receptor and
belongs to the NK group 2 (NKG2) of receptors as member
D. It has also been classiﬁed as killer cell lectin-like
receptor of the subfamily K, member 1 (KLRK1) [16].
NKG2D (KLRK1) is encoded by the Nkg2d (Klrk1) gene
that is located within the NK gene complex (NKC) situated
on chromosome 6 in mice and on chromosome 12 in
humans [17, 18]. NKG2D is atypical incomparison with
other NK receptors. Although NKG2D belongs to the
NKG2 family, it does not share most of their properties. In
contrast to other members of the family (NKG2A/B,
NKG2C, and NKG2E), which form heterodimers with
CD94 and recognize MHC class Ib molecules (HLA-E in
humans and Qa1 in mouse), NKG2D is a homodimer and
recognizes a number of stress induced MHC class I-like
ligands [2, 19]. There is no inhibitory counterpart known
for NKG2D and NKG2D is capable of overriding signals
provided by inhibitory receptors on NK cells engaging
MHC class Ia and Ib molecules. Thus, NKG2D plays a role
as a molecular sensor detecting ‘‘induced self’’ on cells in
danger, which is mostly triggered by viral infections and by
factors causing DNA damage and tumor transformation
[19, 20].
The NKG2D receptor consists of two disulﬁde-linked
type II transmembrane proteins with positively charged
amino acid residues in their transmembrane domains and
very short intracellular tails that do not have any signaling
properties [21]. Signal transduction operates through two
adaptor proteins, DAP10 and DAP12, which associate with
the receptor as homodimers [22, 23]. The NKG2D
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123signaling complex appears as a hexameric structure since
each NKG2D homodimer binds two adaptor homodimers
[24]. In mice, there are two NKG2D isoforms that differ in
length of their intracellular sequence by 13 amino acid
residues and have different association properties for the
two adaptor proteins. The short isoform of NKG2D
(NKG2D-S) associates with both adaptor proteins, while
the long one (NKG2D-L) only binds to DAP10 [22, 23,
25]. Humans possess only the NKG2D-L isoform.
DAP10 has a YINM motif in its cytoplasmatic tail
which, upon phosphorylation, recruits the p85 subunit of
phoshpoinositide-3-kinase (PI3K) and Grb2–Vav1. This
signal stimulates survival and cytotoxicity of NK cells and
provides co-stimulation to activated T cells [26–28].
DAP12 possesses an immunoreceptor tyrosine-based acti-
vation motif (ITAM) which, after phosphorylation, recruits
Src family kinases ZAP70 and Syk, responsible for cyto-
kine release and enhancement of cytotoxicity in NK cells
[29]. Even though there are some reports that DAP12 can
also be expressed by T cells [30], deﬁciency of DAP10
results in complete loss of NKG2D signaling in T cells and
therefore appears to be the most important adaptor for
NKG2D signaling in these cells [13, 22, 23].
NKG2D is able to bind a number of MHC class I-like
ligands because of its unique protein structure [31–33]. In
mice, it binds to the family of retinoic acid early inducible
proteins (Rae1) [34, 35]. There are ﬁve members of these
GPI-anchored proteins (Rae1-a,- b,- c,- d, and -e) and their
expression differs between mouse strains [19]. NKG2D
also binds to the closely related group of histocompatibility
antigen 60 (H60) glycoproteins, which consists of three
members (H60a–c). H60a and b are transmembrane pro-
teins, while H60c is GPI-anchored [36–38]. Whereas H60a
is widely expressed, H60b and c proteins display highly
tissue- (but not mouse strain)-speciﬁc expression patterns
[19]. Murine UL-16-binding protein-like transcript 1
(MULT1), which binds NKG2D with the highest afﬁnity of
all ligands, is so far the only transmembrane glycoprotein
that belongs to the third group of murine NKG2D-binding
proteins [39, 40].
In humans, NKG2D binds to the MHC class-I related
proteins MICA and MICB (MHC class I chain-related
protein A and B) [1]. NKG2D also recognizes surface
glycoproteins that bind human cytomegalovirus (HCMV)
UL-16 protein (ULBPs) [12, 41–43]. There are six mem-
bers of the ULBP family of proteins, which are closely
related to the Rae1 molecules in mice. ULBP1, -2, and -3
and -6 are GPI-anchored, while RAET1E and -G (also
known as ULBP4 and ULBP5) are transmembrane pro-
teins. NKG2D ligands are mostly induced by cellular stress
(‘‘induced self’’), although some of them are expressed at
low levels in different tissues [37–39, 44]. However,
expression of the ligands is very tightly controlled at
transcriptional or/and posttranscriptional levels, since
unbalanced expression may trigger activation of the
immune system and autoimmune responses [45].
NKG2D in the control of viral infections
Viruses, as intracellular pathogens, are usually efﬁciently
controlled by NK and CD8
? T cells. NK cells limit viral
replication and viral load in different tissues early upon
infection, while CD8
? ab T cells are responsible for the
ﬁnal viral clearance and, in some cases, for the establish-
ment of viral latency. NKG2D is expressed on both of these
cell types and plays an important role in the control of viral
infections. Different viruses are able to induce expression
of NKG2D ligands on infected cells [46–49]. They cause
strong activation of NK cells as well as enhancement of
antiviral effector functions of activated CD8
? ab T cells,
which can be prevented by NKG2D-speciﬁc mAbs [1, 13,
46, 48, 50]. Thus, NKG2D-mediated control represents a
powerful and efﬁcient mechanism to cope with viral
infections.
However, the NKG2D-mediated immunosurveillance
may exert considerable selective pressure on viruses in the
course of the co-evolution with their hosts. Therefore, it is
not surprising that some of them have developed mecha-
nisms to evade NKG2D-mediated activation of the immune
system [14].
Cytomegaloviruses (CMVs) have particularly well-
developed mechanisms of interference with NKG2D-
mediated immune cell activation. The HCMV-encoded
membrane glycoprotein UL16 binds the NKG2D ligands
ULBP1, ULBP2, and MICB [12, 51, 52], thus preventing
their expression on the cell surface. HCMV gene product
UL142 retains ULBP-3 in the cis-Golgi complex and pre-
vents its transport to the membrane [53]. UL142 also
retains newly synthesized full-length MICA (allele 001) in
the cis-Golgi [54, 55]. Interestingly, the MICA allele 008,
which lacks the cytoplasmatic domain, shows resistance to
UL142 binding. The fact that the truncated form of MICA
is the most common allele in several human populations
suggests a profound advantage of the hosts’ ability to
control virus infection through NKG2D-dependent activa-
tion of NK cells [56].
Although MICA and MICB genes are transcribed in all
cells [57], their translation in healthy cells is repressed by
endogenous cellular miRNAs [58]. Viruses exploit these
structures to prevent NKG2D ligand upregulation. For
example, the HCMV-derived miRNA, miR-UL112, pro-
tects infected cells from NKG2D-mediated lysis by acting
as a sponge for MICB mRNA [59].
Mouse cytomegalovirus (MCMV) has also been shown
to extensively downregulate NKG2D ligands. Four viral
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m145 downmodulates cell surface expression of MULT-1
[60], m152 interferes with the expression of Rae1 and H60
proteins [61, 62], while m155 is involved in downmodu-
lation of H60 [63]. In addition, m138/fcr-1 plays an
important role in downmodulation of MULT-1, Rae1e and
H60 [64, 65].
Kaposi’s sarcoma-associated herpesvirus (KSHV)
immune evasion gene K5 reduces cell surface expression
of MICA and MICB as well as of the NKp80 ligand acti-
vation-induced C-type lectin (AICL) via ubiquitination of
lysine residues in cytoplasmic tails of the ligands [66].
Epstein–Barr virus (EBV) can cause B cell lymphomas
in immunosuppressed patients. EBV-transformed B cell
lines express a high level of MHC class I molecules ren-
dering them NK cell-resistant. However, reactivating latent
EBV in transformed B cells increases susceptibility to
NKG2D- and DNAM1-dependent NK cell lysis [67].
Ectromelia virus (ECTV) belongs to the orthopoxvirus
genus, which includes variola virus (VARV), the causative
agent of smallpox, and vaccinia virus (VV). Depletion of
NK cells in mousepox-resistant mouse strains (C57BL/6)
results in massive viremia and death [68]. ECTV induces
expression of NKG2D ligands on infected cells. Neutral-
ization of NKG2D recognition by antibodies causes
increased viral titers and mortality [46]. Zoonotic ortho-
poxviruses (monkeypox and cowpox viruses) encode for a
soluble antagonist of NKG2D [69]: orthopoxvirus MHC
class I-like protein (OMCP). OMCP, which is conserved
among cowpox and monkeypox viruses, is secreted by
infected cells and blocks recognition of NKG2D ligands
[69]. Binding of OMCP causes internalization of NKG2D,
thus lowering the amount of available NKG2D receptor
and inhibiting NKG2D-dependent killing by NK cells [69].
Human immunodeﬁciency virus (HIV)-encoded protein
Nef (negative factor) has been shown to downregulate
expression of the NKG2D ligands MICA, ULBP1, and
ULBP2 on Jurkat and primary CD4
? T cells in vitro [70],
in addition to HLA-A and -B [71]. In contrast to Nef,
another HIV-encoded protein Vpr (viral protein R) has
recently been shown to upregulate expression of NKG2D
ligands ULBP1, -2, -3, but not MICA or MICB, both in
vitro and in vivo [72]. Vpr causes upregulation of the
ligands through activation of DNA damage/stress-sensing
ATR kinase [48]. It seems that Vpr not only contributes to
HIV-1-induced CD4
? T-lymphocyte depletion but also
takes part in HIV-1-induced NK cell dysfunction [72].
In conclusion, NKG2D-mediated control appears to be
an important and powerful mechanism in the immunosur-
veillance of viral infections. A number of viral evasion
mechanisms targeting the NKG2D pathway just emphasize
its importance and this fact should be seriously considered
in the development of future vaccines.
NKG2D in the control of cancer
The potential role of NKG2D in cytotoxic anti-tumor
responses was quickly recognized and discussed as a
revival of the tumor surveillance model [73]. Early
experiments showed that overexpression of NKG2D
ligands in cancer cells caused tumor rejection after trans-
plantation in mice [74, 75]. In humans, it was found that
expression of NKG2D ligands highly correlated with the
amount of T cell inﬁltrates in solid tumors [76]. Paradox-
ically, some tumors were shown to actively upregulate
NKG2D ligands, making them prone to recognition by NK
cells and cytotoxic T cells [76]. Various explanations have
been proposed for this observation. As described in the
previous section, viral infection leads to upregulation of
NKG2D ligands. Some virally induced tumors therefore
show enhanced expression of these proteins in vivo [77].
However, also tumors without viral origin can have high
levels of NKG2D ligands, suggesting a different cause.
One hypothesis is that induction of NKG2D ligands is the
result of the oncogenic process itself. NKG2D ligands are
stress-response genes and are upregulated by stimuli such
as DNA damage [20, 78], heat-shock [44, 79], and shifts in
hormone levels [80]. Many, if not all of these process
readily occur in cancer cells. Oncogenesis is usually
associated with genomic instability [81], heat-shock pro-
teins are often hijacked by tumor cells to promote their
survival [82] and many tumors, such as breast, endometrial
and ovarian cancers use estrogens to promote their growth
[83]. In addition, rapidly proliferating cells have been
shown to induce NKG2D ligands [84]. Upregulation of
these molecules in cancer cells might therefore be a
bystander effect of the oncogenic process. Preventing lysis
by NKG2D-expressing NK and CD8 T cells must therefore
be a feature that a cancer cell acquires in order to sustain its
growth.
Multiple strategies are used by cancer cells in order to
prevent NKG2D mediated killing. The ﬁrst and most
obvious strategy is downmodulation of NKG2D ligands.
Despite signiﬁcant amounts of DNA damage or expression
of heat-shock proteins, many tumors have been shown to
actively inhibit NKG2D ligand expression [9, 85–87]. An
important mechanism for NKG2D ligand downregulation
appears to be the production of immunomodulatory cyto-
kines such as TGFb, which can be directly excreted by
tumor cells themselves, or by regulatory immune cells that
are expanded during tumor progression [88–91]. In addi-
tion to this system, tumors decrease surface NKG2D ligand
expression via shedding of the extracellular domain by
metalloproteases or with the assistance of the disulphide-
isomerase ERp5 [92, 93]. Thirdly, expression of NKG2D
ligands is actively regulated by microRNAs, and tumor
cells also have been shown to manipulate this system via
Regulatory role of NKG2D 3521
123miRNA overexpression [58]. Experimental evidence for
the in vivo relevance of NKG2D ligand downmodulation in
the formation of tumors was recently shown in mice deﬁ-
cient for NKG2D. In animal models for spontaneous tumor
formation, absence of NKG2D resulted in enhanced for-
mation of aggressive tumors. In addition, these tumors
were shown to have increased expression of Rae1 mole-
cules on their surface [9].
Some tumors exploit an opposite strategy to manipulate
NKG2D mediated signaling and instead induce high levels
of its ligands [94]. This concept remained relatively ill-
understood until it was mimicked in mice overexpressing
Rae1 and MICA molecules [15, 95, 96]. In these animals,
surface expression of NKG2D was greatly reduced, both on
NK cells and on CD8 T cells, resulting in impaired anti-
tumor responses by these immune cells [15, 95]. Interest-
ingly, the impact of NKG2D ligand overexpression on CD8
T cell responses against pathogens appears to depend
highly on the model used. Infection of transgenic mice with
L. monocytogenes resulted in reduced anti-bacterial CD8 T
cell numbers [15]. Antiviral responses upon mCMV
infection, on the other hand, did not functionally impair
CD8 T cell responses [96]. One explanation for these
observations may be the differential co-stimulation of CD8
T cells upon infection with different pathogens. Unlike
CD28 triggering, NKG2D co-stimulation is not required
for T cell function [97]. Rather, NKG2D engagement
appears to enhance the cytotoxic capacity of these cells. It
will therefore depend on the pathogen or kind of tumor
encountered to what extent NKG2D signaling is required
for T cell-mediated cytotoxicity.
For NK cells, NKG2D is a directly activating receptor
and NK cell function was impaired in MICA- and Rae1e-
transgenic animals. Not surprisingly, both in vivo and in
vitro killing of tumor cells expressing NKG2D ligands by
NK cells of these mice was reduced. Oppenheim and
coworkers also suggested that constitutive engagement of
NKG2D impaired NK cell function beyond its downmod-
ulation and subsequent inability to engage its ligands on
tumor cells [95]. However, other studies that directly
addressed this issue indicate that this is not the case [15,
96]. Interestingly, NKG2D downmodulation via hyper-
stimulation appears to have different effects than inhibition
of NKG2D signaling by omitting the molecules involved
in transducing NKG2D-signaling. Downmodulation of
NKG2D via antibody treatment or in Rae1 transgenic
animals resulted in increased tumor cell growth in a model
of chemically induced cancer formation [95, 98]. However,
the same model showed no differences when NKG2D-
deﬁcient animals were compared with wild type controls
[9]. The explanation for these differences is currently
lacking, but it appears likely that NKG2D hyperligation
induces compensatory and/or regulatory mechanisms
which are absent in NKG2D-deﬁcient animals.
In support of this notion is the observation that NKG2D
stimulation promotes the speciﬁc outgrowth of regulatory
T cell subsets in humans. NKG2D ligation enhances pro-
liferation of a characteristic regulatory NKG2D
?CD4
? T
cell pool that is rare under normal conditions [6, 99]. This
cell subset produces IL-10 and TGFb, thus inhibiting
immune responses in a paracrine fashion [99]. In addition,
these cells express high levels of Fas ligand (FASL), which
induces apoptosis in neighboring activated T cells, whereas
these regulatory cells themselves appear refractory to this
FASL [6]. Apart from directly presenting NKG2D ligands
in cis, human tumor cells can manipulate the immune
system by releasing a soluble form of NKG2D ligands.
With the help of metalloproteases or of the cell surface-
bound protein ERp5, the NKG2D ligands MICA, MICB,
and ULBP2 are cleaved of the membrane and are capable
of affecting NKG2D expressing cells in trans [100–102]. In
addition, ULBP4 can be expressed in soluble form via
alternative splicing [103]. Apart from producing soluble
proteins, tumor cells produce exosomes with high levels of
NKG2D ligands [104, 105]. Both soluble ligands and
ligands expressed on exosomes have been shown to
downmodulate NKG2D on cytotoxic cells and thus impair
their anti-tumor activity.
In summary, it appears that tumor cells in general adapt
methods to inhibit NKG2D signaling. They do this either
via downmodulation of NKG2D ligands or via hyperex-
pression of NKG2D ligands on their surface or in soluble
form. In addition, however, there are also tumors that do
not seem to modify the NKG2D signaling pathway at all,
yet still escape from destruction. These tumors also arise
in experimental models [9], indicating that there is a
‘third’ method to avoid NKG2D-mediated killing. The
molecular mechanism behind this phenomenon has yet to
be revealed.
Due to its prominent role in tumor cell biology, the
NKG2D signaling pathway has been under extensive
investigation in the cancer ﬁeld, both as a diagnostic tool
and as a therapeutic target. MICA has been shown to be
one of the most polymorphic genes within the group of
MHC class I-related molecules [106] and several alleles,
supposedly of reduced NKG2D afﬁnity, have been asso-
ciated with cancer [107–109]. Also, expression of NKG2D
ligands, both the soluble and the membrane-bound form,
has been shown to be a reliable marker for disease pro-
gression in a variety of malignancies [85, 94, 110],
illustrating its value as a clinical marker.
Induction of NKG2D ligand expression on tumors
appears to be a promising therapeutic strategy in cancer.
Expression of the NKG2D ligand MULT1 is low under
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tion and subsequent targeting to the proteasome. In stressed
cells, this ubiquitination process is inhibited, leading to
rapid upregulation of surface-bound MULT1 [45, 111]. In
tumor cells, NKG2D ligand expression can therefore be
speciﬁcally induced with proteasome inhibitors, making
tumors sensitive to NKG2D-mediated killing [112]. In
addition, HDAC inhibitors appear to stimulate NKG2D
ligand expression on tumor cells and their immunogenicity
for allogeneic NK cells [113].
Finally, the NKG2D receptor system has been used as a
target for anti-cancer therapy. Therapeutic MICA-speciﬁc
antibodies effectively opsonized cancer cells and induced
DC-mediated cross-presentation of tumor antigens [114].
Bifunctional proteins consisting of a tumor-antigen direc-
ted antibody fused to NKG2D ligands effectively ‘coated’
tumor cells with activating ligands and increased their
killing [115, 116].
In summary, the two sides of NKG2D in tumor biology
make this protein a key molecule of interest for future
oncological research. On one hand, the NKG2D receptor
system may be exploited in anti-tumor strategies, and on
the other hand, over-stimulation of NKG2D should be
prevented in order to potentiate tumor surveillance.
NKG2D in autoimmunity
As previously mentioned, inappropriate or deregulated
expression of NKG2D ligands on healthy cells can break
the delicate balance between immune activation and tol-
erance, and trigger autoimmune response [117]. Several
autoimmune diseases have therefore been associated with
NKG2D signaling.
Insulin-dependent diabetes mellitus/type 1 diabetes
(T1D) is a chronic autoimmune disorder in which insulin-
producing Langerhans islets are destroyed by autoreactive
immune cells. Genetic linkage studies have shown that
some MICA alleles are positively associated with human
T1D, but the functional relevance of this polymorphism is
far from clear [118, 119]. The nonobese diabetic (NOD)
mouse is widely studied as a model of human T1D [120].
Prediabetic NOD mice express Rae1 ligands on their islet
cells [121]. The development of disease can be completely
prevented by treatment with NKG2D-blocking mAbs,
which reduce expansion and function of autoreactive CD8
?
T cells [10].
Rheumatoid arthritis (RA) is a chronic systemic
inﬂammatory disorder in which immune cells, especially T
cells, cause inﬂammation and destruction of the joints
[122]. RA patients have high levels of IL-15 and TNF-a in
the sera and inﬂamed joints [5], which induce expression of
NKG2D on CD4
?CD28
- subset of T cells [5]. Since
MICA and MICB molecules are also dramatically upreg-
ulated in RA synoviocytes, they activate the T cells in an
NKG2D-dependent manner [5].
Celiac disease is an autoimmune disorder of the small
intestine that occurs in genetically susceptible individuals
as a reaction to wheat gliadin protein [123]. One of the
diagnostic hallmarks of celiac disease is a massive inﬁl-
tration of intraepithelial NKG2D
? CD8
? cd T lymphocytes
(IELs) in the gut [124]. MIC proteins, normally found
intracellularly in enterocytes, become strongly expressed
on the surface of epithelial cells in patients with active
disease. There is evidence that this process is IL-15-
dependent [125, 126].
Crohn’s disease (CD) belongs to the group of inﬂam-
matory bowel diseases. Signiﬁcantly increased levels of
MIC expression were found on intestinal epithelial cells. It
has been shown that the number of intestinal epithelial
CD4
? T cells expressing NKG2D highly correlates with
the amount of intestinal inﬂammation and therefore are
thought to play an important role in disease progression [4].
NKG2D in NK cell development
NKG2D is expressed very early in the development of NK
cells, already at the stage of NK precursors (NKPs), the
earliest NK committed cells [127]. About 10% of CD122
?
NK1.1
- NKPs (stage I) exhibit this receptor on the cell
surface, whereas all immature NK cells (stage II and III)
express NKG2D. During these stages of NK cell devel-
opment, NKG2D expression rapidly increases and remains
high through all later stages of maturation [127, 128].
Recently, the intracellular signaling components of
IL-15R and NKG2D have been shown to be coupled [129].
IL-15 is an essential cytokine for the development and
survival of NK cells [130, 131]. Mice deﬁcient for IL-15,
IL-15Rb, or any of the components of the IL-15 signaling
pathway (e.g., Jak3, STAT5) have severe defects in NK
cell development [132–136]. Horng et al. [129] have cre-
ated a transgenic mouse strain expressing a DAP10 protein
fused with the monoubiquitin (DAP10-Ub), which directly
targets this molecule for proteasomal degradation. These
mice display completely abolished NKG2D expression on
T cells and severely reduced expression of this receptor on
NK cells, which also express the NKG2D adaptor molecule
DAP12. They observed severe defects in NK cell devel-
opment because of their failure to respond to IL-15
stimulation. Jak3 has been shown to be the essential kinase
downstream of the IL-15 receptor that is responsible for
DAP10 phosphorylation important for the activation of
STAT5, a prime target of Jak3. In addition, it was found
that DAP10 can associate with the IL-15R b and c (Fig. 1).
Interestingly, in contrast to DAP10-Ub mice, defects in NK
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-/- mice [23].
This could be explained by redundancy of the system, since
intact NKG2D–DAP12 complexes on the surface of NK
cells could compensate the lack of DAP10 to a major
extent, despite a reduction in NKG2D expression. Activa-
tion of Syk by DAP12 can regulate survival and
cytotoxicity via activation of PI3K [137, 138].
Considering the above-mentioned ﬁndings, the question
is whether and how NKG2D is involved in the develop-
ment of NK cells. In transgenic mouse models with
sustained expression of NKG2D ligands (MICA, Rae1e,
Rae1c) and consequent downmodulation of NKG2D,
impairments in the NK cell development were not observed
[15, 95, 96]. In these models this may be the result of low-
level expression of the receptor complexes on the cell
surface and persistent NK cell stimulation.
To resolve this issue, recently two models of NKG2D-
deﬁciency were reported [9, 139]. In the Klrk1
-/- mice
generated by Guerra et al. [9], the authors did not ﬁnd any
major developmental defects, although they showed mild
changes in some subpopulations of NK cells (i.e. Ly49A
?
cells). In Klrk1
-/- mice generated in our lab, NK cell
development was moderately affected [139]. In the absence
of NKG2D we observed perturbations in the size of some
developmental subsets of NK cells, increased proliferation
of immature NK cells (mostly in stage II), their faster
maturation and increased sensitivity to apoptosis. In addi-
tion, NK cell-mediated control of MCMV infection in these
mice was better than in littermate controls, which we
ascribed to the dysregulation and faster maturation of NK
cells in the absence of NKG2D.
Differences in targeting strategies may be responsible
for the observed effects. Our targeting inserted the EGFP
sequence in the third exon of the Klrk1 locus, which could,
as a foreign genetic element, cause non-speciﬁc effects.
Therefore, we generated Klrk1
D/D mice in which the EGFP
cassette is not present (Fig. 2a). These mice were obtained
from the breeding of Klrk1
ﬂox/ﬂox mice (our unpublished
data) and Cre ‘deleter’ mice, which resulted in the elimi-
nation of the ﬂoxed second and third exon of the Klrk1
gene in vivo, a mutation that was further propagated as
Klrk1
D/D. After we conﬁrmed that NK cells from Klrk1
D/D
mice do not express NKG2D (Fig. 2b), we analyzed the
various stages of NK cell development in Klrk1
-/- versus
Klrk1
D/D mice in comparison to wt animals (Fig. 3a).
Klrk1
D/D mice displayed alterations in cell surface marker
expression and maturation stages on NK cell subsets that
were very similar to those seen in Klrk1
-/- animals. In
addition, both mouse strains controlled early MCMV rep-
lication in a highly comparable manner (Fig. 3b). Thus,
these data strongly argue that the previously observed
phenotype of NK cells in our Klrk1
-/- mice [139] is the
consequence of the desired Klrk1 mutation rather than of a
genetic deregulation caused by the EGFP sequence.
Fig. 1 Coupling of the IL-15R and NKG2D signaling components in
NK cells. The ﬁgure roughly summarizes interactions between
signaling components of the IL-15R and NKG2D, which was
proposed by Horng et al. [129]. Jak3, as a part of canonical IL-15R
signaling pathway, is essential for the phosphorylation of DAP10.
Activated DAP10 recruits PI3K and Grb2, which control prolifera-
tion, survival, and cytotoxicity of NK cells. DAP10 also associates
with IL-15Rb and -c chains
Fig. 2 Comparison of Klrk1
-/- and Klrk1
D/D mice. a Different
mutations of the Klrk1 locus (upper row)i nKlrk1
-/- (middle row)
and Klrk1
D/D (lower row) mice are shown. Klrk1
D/D mice were
obtained from the breeding of Klrk1
ﬂox/ﬂox and Cre deleter mice.
b NKG2D expression on CD3
-CD19
-NK1.1
? cells isolated from the
spleen of Klrk1
-/- (left panel) and Klrk1
D/D (right panel) mice is
shown
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123In conclusion, NKG2D appears to play an important role
in NK cell development. It seems that its role in the early
development of NK cells is different than during the
mature stages where NKG2D is responsible for activation
of effector functions. ‘‘Unleashed’’ proliferation of imma-
ture NK cells and their increased sensitivity to apoptosis in
the absence of NKG2D suggest that this receptor plays
rather a regulatory role at this stage, most probably in
concert with IL-15R and perhaps some other receptors
(Fig. 1), controlling proliferation and survival of NK cells.
Future research must reveal whether this function is limited
to NK cells or whether other cellular subsets that consti-
tutively express NKG2D (most notably NKT and cd T
cells) are also affected.
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